Table 4.
Univariate analyses of the combined impact of CMV serostatus, donor source, and PTCy on transplant-related outcomes
| Outcomes | Recipient positive | Donor positive/recipient negative | Both donor and recipient negative | P | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HaploCy (N = 563) | SibCy (N = 284) | SibCNI (N = 1086) | HaploCy (N = 54) | SibCy (N = 36) | SibCNI (N = 163) | HaploCy (N = 131) | SibCy (N = 79) | SibCNI(N = 327) | |||||||||||
| N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | N | Prob (99% CI) | ||
| Overall survival | 563 | 284 | 1086 | 54 | 36 | 163 | 131 | 79 | 327 | <.001 | |||||||||
| 100 days | 84.7 (80.6-88.4)% | 89.1 (83.9-93.4)% | 91.1 (88.7-93.2)% | 92.6 (81-99)% | 88.9 (72.3-98.4)% | 93.9 (88.2-97.8)% | 90.1 (82.4-95.7)% | 91.1 (81.3-97.5)% | 93.9 (90-96.8)% | .001 | |||||||||
| 2 y | 46.4 (40.6-52.3)% | 54.5 (46.4-62.5)% | 57.3 (53.3-61.3)% | 51.7 (32.5-70.6)% | 59.9 (38.1-79.8)% | 52.1 (41.7-62.5)% | 60.3 (48-72)% | 63.1 (47.8-77.1)% | 68 (61-74.6)% | <.001 | |||||||||
| Relapse | 554 | 280 | 1078 | 53 | 36 | 161 | 130 | 79 | 321 | .263 | |||||||||
| 100 days | 8.3 (5.5-11.6)% | 8.6 (4.8-13.4)% | 14.3 (11.7-17.2)% | 9.4 (1.8-22.2)% | 8.3 (0.6-23.9)% | 17.4 (10.4-25.7)% | 7.7 (2.8-14.8)% | 10.1 (3.1-20.5)% | 11.5 (7.3-16.5)% | .002 | |||||||||
| 2 y | 37.8 (32.3-43.5)% | 37 (29.4-44.8)% | 39.2 (35.4-43.2)% | 37 (20.4-55.4)% | 33.7 (15-55.5)% | 49.7 (39.4-60.1)% | 44.3 (32.3-56.7)% | 49.4 (33.9-65)% | 36.1 (29.2-43.3)% | .098 | |||||||||
| Nonrelapse mortality | 554 | 280 | 1078 | 53 | 36 | 161 | 130 | 79 | 321 | <.001 | |||||||||
| 100 days | 12.6 (9.2-16.5)% | 9.6 (5.6-14.7)% | 5.4 (3.8-7.3)% | 5.7 (0.4-16.5)% | 8.3 (0.6-23.9)% | 2.5 (0.3-6.6)% | 7.7 (2.8-14.8)% | 6.3 (1.2-15.2)% | 3.7 (1.5-6.9)% | <.001 | |||||||||
| 2 y | 26.2 (21.4-31.4)% | 18.6 (12.8-25.1)% | 14.7 (12-17.6)% | 18.2 (6.2-34.7)% | 25 (9-45.7)% | 11.6 (5.8-19.1)% | 12.8 (6.1-21.6)% | 15.2 (5.9-27.9)% | 12.1 (7.8-17.3)% | <.001 | |||||||||
| Grade 2-4 acute GVHD | 556 | 281 | 1071 | 54 | 34 | 160 | 130 | 79 | 322 | .891 | |||||||||
| 100 days | 32.6 (27.6-37.9)% | 31 (24.1-38.3)% | 29.3 (25.8-33)% | 35.5 (19.7-53.1)% | 29.4 (11.6-51.3)% | 25.7 (17.4-35.1)% | 28.6 (19-39.3)% | 36.7 (23.4-51.2)% | 28 (21.8-34.6)% | .588 | |||||||||
| 6 mo | 33.9 (28.8-39.2)% | 33.6 (26.5-41)% | 33.5 (29.8-37.3)% | 35.5 (19.7-53.1)% | 29.4 (11.6-51.3)% | 29.5 (20.7-39.2)% | 29.4 (19.6-40.2)% | 38 (24.5-52.5)% | 33.3 (26.7-40.3)% | .919 | |||||||||
| Chronic GVHD | 563 | 283 | 1084 | 54 | 36 | 163 | 131 | 79 | 327 | <.001 | |||||||||
| 6 mo | 16.8 (12.7-21.3)% | 15.9 (10.5-22.1)% | 22.4 (19.1-25.9)% | 11.8 (2.8-25.8)% | 19.7 (5.6-39.6)% | 18.3 (11.1-26.8)% | 19.4 (11.1-29.3)% | 20.4 (9.7-33.8)% | 20.5 (14.9-26.7)% | .101 | |||||||||
| 2 y | 35.2 (29.4-41.3)% | 34.9 (26.9-43.4)% | 54.3 (50-58.6)% | 26.1 (11.1-44.7)% | 43.6 (21.4-67.2)% | 52.1 (40.8-63.3)% | 39.9 (28.2-52.2)% | 40.2 (25.3-56.1)% | 55.8 (48.1-63.4)% | <.001 | |||||||||
Cy, posttransplant cyclophosphamide; Prob, probability.